- Tension: Some 80-year-olds outperform their younger siblings on cognitive tests, and genetics alone can’t explain the gap. A single protein may hold the answer.
- Noise: The supplement industry is already trying to monetize klotho before science can deliver it therapeutically, while generic advice about ‘staying active’ has long lacked a concrete biological mechanism to back it up.
- Direct Message: Klotho research is shifting cognitive decline from an inevitable mystery to a molecular process with identifiable levers, giving people not a cure but something they haven’t had before: a specific biological reason to believe prevention efforts actually reach the brain.
To learn more about our editorial approach, explore The Direct Message methodology.
Diane Hartley, a 79-year-old retired school principal in Tucson, scores higher on cognitive tests today than she did at 62. Her neurologist calls her a “superager.” Her daughter calls it luck. Diane calls it a mystery, because she doesn’t meditate, she’s never touched a crossword puzzle with any real consistency, and she eats more red meat than any longevity influencer would ever endorse. Meanwhile, her younger brother, 71, has been struggling with early-stage cognitive decline for three years. Same parents. Same childhood home. Same gene pool, more or less. So what’s different?
For decades, researchers have tried to answer that question by looking at behavior: exercise, diet, social engagement, sleep. All of those matter. But a growing body of evidence suggests the real dividing line may be molecular, and one protein in particular has started to dominate the conversation in neuroscience labs around the world.
The protein is called klotho. Named after the Greek goddess who spins the thread of life, klotho was first identified in 1997 by a Japanese research team studying mice that aged rapidly when the gene encoding it was disrupted. Those mice developed conditions typically associated with old age: hardened arteries, cognitive decline, shortened lifespans. When researchers later engineered mice to overexpress klotho, the opposite happened. The animals lived longer. Their brains stayed sharp. Something about this protein seemed to act as a biological shield against the wear and tear of time.
Fast forward to 2023 and 2024, and klotho has moved well beyond mouse models. A landmark study published in Nature found that injecting klotho into aging mice improved their synaptic plasticity and cognitive function within days. The effect was remarkable: old mice began performing spatial memory tasks at levels comparable to much younger animals. The researchers, led by Dena Dubal at UC San Francisco, described klotho as functioning like a “cognitive enhancer” that works not by stimulating neurons directly but by improving the environment in which they operate.
This is the part that caught the attention of people like Marcus Ellison, a 54-year-old software engineer in Portland who lost his mother to Alzheimer’s at 68. Marcus has been tracking every new Alzheimer’s study for a decade. He’s tried lion’s mane supplements, intermittent fasting, cold plunges. “Every year there’s a new miracle fix,” he told me. “I’ve become skeptical of all of it. But klotho feels different because they’re not just saying it correlates with something. They’re showing a mechanism.”
He’s right to notice that distinction. Most cognitive decline interventions operate at the level of association. We know that people who exercise tend to have better brain function in old age, for instance, but the causal chain is complex and tangled. Klotho research has started to untangle one specific thread: the protein appears to enhance a neurotransmitter receptor called NMDA, which is critical for learning and memory. When klotho levels are high, NMDA receptor function improves. When they’re low, synaptic communication degrades.
As we’ve explored in prior coverage of superagers and the proteins that protect their brains, some people seem to produce more klotho naturally. That genetic variation may explain a good deal of the gap between someone like Diane and her brother. But the exciting part is that klotho levels aren’t purely genetic. They can be influenced.
Exercise, for example, has been shown to raise circulating klotho levels. A 2021 study in Brain, Behavior, and Immunity found that even moderate aerobic activity increased klotho expression in older adults over a 16-week period. That finding reframes something we already thought we knew. Exercise helps the brain, yes, but part of how it helps may be by boosting klotho, which in turn protects the synaptic machinery that keeps cognition running smoothly.
Reena Patel, a 47-year-old geriatrician in Chicago, has been following the research closely. She works with patients in various stages of cognitive decline, and she says the most common question she gets from families is some version of: “Is there anything we can actually do?” She used to feel limited in her answers. Now, she says, the klotho findings give her a more concrete framework. “I’m not prescribing klotho. That’s not available yet. But when I explain to a family that physical activity, stress reduction, and metabolic health all converge on the same molecular pathway, it changes how they think about prevention. It stops feeling vague.”
That convergence is worth sitting with. Because the supplement industry has already started circling klotho like it’s the next big thing, and the nuance matters. As one writer’s experience with brain health supplements showed, stacking interventions without understanding how they interact can actively undermine your goals. There is no klotho pill. There are companies selling “klotho-boosting” formulas that have no peer-reviewed evidence behind them. The protein itself is large, fragile, and difficult to deliver therapeutically, which is why Dubal’s team injected a fragment of it directly in their mouse studies rather than relying on oral supplementation.
What does exist, and what researchers are cautiously optimistic about, is the possibility of a klotho-based therapeutic within the next decade. Several biotech companies are exploring synthetic klotho fragments and delivery mechanisms that could cross the blood-brain barrier. If successful, this wouldn’t be a cure for Alzheimer’s or dementia. It would be something potentially more useful: a way to slow the degradation that precedes those diagnoses by years, even decades.
And that timeline matters because of what we’re learning about how early cognitive decline actually begins. Research on environmental factors like forever chemicals has shown that biological aging can be accelerated by exposures that start decades before symptoms appear. Klotho levels begin declining in most people around age 40. By 70, they’re often at a fraction of what they were. The window for intervention, in other words, is much wider than most people assume.
James Whitfield, a 63-year-old retired firefighter in Baltimore, started paying attention to klotho research after his annual cognitive screening showed mild decline. “My doctor said it was normal aging,” he told me. “But ‘normal aging’ is what they told my dad, too, and by 75 he didn’t recognize my mother.” James has since increased his exercise, improved his sleep, and started working with a nutritionist. He has no idea what his klotho levels are, because there’s no widely available clinical test for it yet. But the research gave him something that generic advice about “staying active” never did: a reason to believe the effort connects to something specific happening in his brain.
That specificity is what’s changing the conversation. For a long time, cognitive decline prevention felt like a collection of soft recommendations. Eat well. Move more. Stay social. All true, all supported by evidence, and all frustratingly abstract when you’re watching someone you love forget your name. Even dietary research pointing to specific eating patterns has sometimes struggled to explain the precise biological why behind its findings.
Klotho doesn’t answer every question. But it offers something that’s been missing from the aging conversation: a visible thread between what we do and what happens inside our skulls at the molecular level. When Diane Hartley aces her cognitive tests, it may be because her body, for reasons partly genetic and partly behavioral, has maintained higher levels of a protein that keeps her synapses communicating clearly. When her brother struggles, it may be because his levels dropped earlier, faster, and without anyone knowing it was happening.
The quiet revolution here has nothing to do with a miracle cure or a supplement you can order online. It’s that we’re beginning to see the aging brain as something with levers, molecular ones, that can potentially be adjusted. And for the millions of people who carry the fear of cognitive decline like a low hum beneath every forgotten word and misplaced key, that shift from mystery to mechanism is its own kind of relief. Not a promise. Not a guarantee. But the first clear signal that forgetting may not be as inevitable as we’ve been told.
Feature image by Tara Winstead on Pexels
